Pharma

Taking stock of the drug industry, from the lab to the medicine chest

Pharmalot

Canada ends a probe into J&J for allegedly thwarting biosimilar competition

By Ed Silverman

Bernie Sanders
Pharmalot

Catalyst tries to mollify an angry Bernie Sanders over the price of its rare disease drug

By Ed Silverman

Pharmalot

Pharmalittle: Pfizer suffers a setback with a best-selling pill; J&J is subpoenaed over baby powder

By Ed Silverman

Jack Stoddard
Business

Unsealed testimony reveals a goal of Atul Gawande venture: ‘Make health insurance intelligible’

By Kate Sheridan

Humira
Pharmalot

Did ‘opportunism’ prompt drug makers to take bigger price hikes after competition arrived?

By Ed Silverman

Kiryat Shmona
Pharmalot

FTC reaches ‘global’ deal with Teva over pay-to-delay deals, but doesn’t fine the company

By Ed Silverman

Kendall Square 1987
Biotech

Developers are scrambling for the next Kendall Square. Where will it be?

By Tim Logan

Pharmalot

Pharmalittle: More institutions rethink Sackler donations; Japan embraces cost effectiveness for drugs

By Ed Silverman

Alexion Pharmaceuticals Inc
Pharmalot

Alexion agrees to pay $13 million for illegally using charities to pay kickbacks to Medicare patients

By Ed Silverman

Pharmalot

Allergan agrees to eventually split top jobs, but big hedge fund calls it a ‘lame’ move

By Ed Silverman

Optum
Pharmalot

Ohio seeks $16m from UnitedHealth’s PBM for overcharging on drugs

By Ed Silverman

Pharmalot

Pharmalittle: Insulin makers must face price-gouging claims; Allergan agrees to independent chair during next transition

By Ed Silverman

MilliporeSigma
Biotech

Stealth player is poised to win a CRISPR patent that could speed the development of therapies

By Sharon Begley

Colorful selection of pills
Pharmalot

Here’s how prosecutors say generic drug makers schemed to fix prices

By Ed Silverman

Hep C San Fran
Pharmalot

The ‘Netflix’ model for hepatitis C drugs is saving Australia a lot of money

By Ed Silverman

Hires
Pharmalot

Up and down the ladder: The latest comings and goings

By Ed Silverman

Pharmalot

Pharmalittle: Company buys drug and raises price 70 percent; Oklahoma opioid trial is the one to watch

By Ed Silverman

Michael Babich
Business

Former Insys CEO said he was made the ‘fall guy’ for opioid maker Insys

By Maria Cramer — Boston Globe

Pharmalot

Italy proposes the WHO set international standards for drug-pricing transparency

By Ed Silverman

Racial bias Pain Management
Pharmalot

Lawmakers ask FDA to explain steps to contain contaminants in blood pressure drugs

By Ed Silverman

Pharmalot

Pharmalittle: A stunning Insys video for boosting Subsys; pain patients complain about prescribing restrictions

By Ed Silverman

Biotech

In rap video, opioid salesmen boasted of their prowess

By Jonathan Saltzman — Boston Globe

China lung cancer scan
Pharmalot

Drug company payments for consulting and speaking influence oncologists’ prescribing

By Ed Silverman

Pharmalot

Pharmalittle: J&J depression drug gets FDA panel nod; Vertex cancels meeting with U.K. official

By Ed Silverman

Michael Babich
Pharma

Former CEO says Insys founder pushed for higher doses of opioid

By Jonathan Saltzman — Boston Globe

New Opioid Approved - Dsuvia
Pharmalot

Lawmakers ask FDA to explain a controversial decision to approve a powerful painkiller

By Ed Silverman

Opioid Lawyers
Pharmalot

More larger-cap biopharma companies faced securities fraud lawsuits than ever

By Ed Silverman

Oxycodone
Pharmalot

FDA scolds McKesson for naproxen in tampered oxycodone bottles, calling incidents ‘simply unacceptable’

By Ed Silverman

David A. Sinclair
Biotech

Longevity scientists launch academy to raise profile of life-extending research

By Robert Weisman — Boston Globe

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy